Merck, Cipla Deny Deal Talks But The Charm Of The Indian Market Stokes Speculations
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Merck CEO designate Kenneth Frazier's visit to India accompanied by key global leaders earlier this month sparked rumors that takeover of a large Indian company could be on Merck's wish list and Cipla - the largest home-grown company by market share - may be the likely target on the Big Pharma's radar
You may also be interested in...
Not Selling Yet, Cipla Opposes Capping MNC-led Buyouts Of Indian Firms
MUMBAI - Cipla Ltd. Chairman Yusuf K. Hamied has tried to temper nagging speculation over a possible sell-off to a global company like Merck & Co. or Takeda Pharmaceutical Co. Ltd. He emphatically denied holding any negotiations and claimed he has never been approached for a potential transaction
Not Selling Yet, Cipla Opposes Capping MNC-led Buyouts Of Indian Firms
MUMBAI - Cipla Ltd. Chairman Yusuf K. Hamied has tried to temper nagging speculation over a possible sell-off to a global company like Merck & Co. or Takeda Pharmaceutical Co. Ltd. He emphatically denied holding any negotiations and claimed he has never been approached for a potential transaction
Asia Spotlight: Innovative, Differentiated Generics To Lead Merck Into Emerging Markets, Says EM President Kevin Ali
MUMBAI – Merck & Co. President for Emerging Markets Kevin Ali likes to understand the “ground feel” of a company, says a senior company executive at its India affiliate MSD, and that need to see things in person may have brought the busy executive trotting back to India in less than three months of signing a “transformative deal” with Sun Pharmaceutical Industries Ltd.